Arvinas (ARVN) Net Income towards Common Stockholders Growth (5y) (2022 - 2026)
Powered by 
Analysis
Arvinas (ARVN) Net Income towards Common Stockholders Growth (5y) (2022 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.26 Bn | 131.41 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.64 Bn | 77.64 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn |
| 4 | Moderna | 57.83 Bn | 52.69 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - |
| 6 | BeOne Medicines | 39.94 Bn | 34.84 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.19 Bn | 31.88 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - |
| 9 | Insmed | 27.35 Bn | 26.19 Bn | 358.27 Mn |
| 10 | Arvinas | 611.71 Mn | 43.81 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 39.95% |
| Mar 31, 2026 | -7.04% |
| Dec 31, 2025 | -11.69% |
| Sep 30, 2025 | -2.54% |
| Jun 30, 2025 | -19.10% |
| Mar 31, 2025 | 41.87% |
| Dec 31, 2024 | -16.46% |
| Sep 30, 2024 | -22.72% |
| Jun 30, 2024 | -15.45% |
| Mar 31, 2024 | -36.95% |
| Dec 31, 2023 | -57.27% |
| Sep 30, 2023 | 12.62% |
| Jun 30, 2023 | -23.54% |
| Mar 31, 2023 | -1.33% |
| Dec 31, 2022 | -53.83% |
| Sep 30, 2022 | -58.15% |
| Jun 30, 2022 | -58.83% |
| Mar 31, 2022 | -57.79% |